This page shows the latest European biotech news and features for those working in and with pharma, biotech and healthcare.
The biotech has also managed to increase its share price since its launch, a feat not frequently achieved in the sector. ... a new surge in confidence in European biotech.
stage European biotechs, which have tended not have access to as much financial support as their counterparts in the US. ... to Medicxi, with European companies growing in stature and offering improved returns on investment for backers.
Boost for UK's golden triangle biotech region. Illumina has set up its first hub for genomics start-up funding outside the US, and has chosen Cambridge in the UK for
to take its stake in the Belgian biotech to 22%, as well as $1.1bn in opt-in payments for two late-stage drug candidates. ... on R&D, said the biotech’s CEO Onno van de Stolpe in a Bloomberg interview.
a European biotech company. ... BioNTech was the first biotech to bring an mRNA-based individualised cancer vaccine targeting neoantigens into clinical trials.
New approach to tackling diseases such as lupus, RA. Dutch biotech Citryll has raised 15m ($17m) in first-round financing to help advance its new therapeutic approach to autoimmune diseases.
More from news
Approximately 21 fully matching, plus 34 partially matching documents found.
Germany is European biotech’s sleeping giant. “Germany is Europe’s great untapped player in biotech,” said Richard. ... produced far fewer biotech companies than you would expect, it’s definitely the place to watch.”.
biotechs’. The growing role of specialist venture capital. One of the key ingredients in these and other recent European biotech success stories is long-term backing from investors. ... European biotech is benefiting from this new support to translate
Cambridge's new Biomedical Campus is home to specialist NHS trusts, AstraZeneca's new HQ and biotech firms. ... How can the UK life science ecosystem produce even more biotech start-ups, and propel them to long-term success?
It’s long been recognised that one of the biggest factors holding back UK and European biotech success has been a paucity of leaders, and that’s why efforts are being ... As well as overseeing the European communications group for Syneos Health, she
Capital markets infrastructure is a barrier. European biotech companies continue to find it hard to raise public money in Europe. ... Pockets of success on Euronext mask the fact that leading European venture groups primarily look to the Nasdaq, at least
More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.
Former general manager for Emmanuel Macron's party to spearhead Paris' bid to attract life sciences investment
With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ... He said: “Apeiron is
He is currently a board member of German biotech Epiontis, and has previously served as chief financial officer of PregLem and chairman of Aimago. ... Prior to this, Dr Zimmerman was a European biotech analyst at UBS Investment Bank.
Farquharson is additionally appointed to the EU Commission's Expert Group, advising on the European Biotech Directive's impact on patent law and R&D activities.
After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at
More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...